Dr. Peter Gasser’s MAPS-sponsored study evaluating LSD-assisted psychotherapy for subjects with anxiety secondary to advanced-stage illness received final approval from the BAG (Swiss DEA) on December 5, Ethics Committee (Swiss IRB equivalent) approval on October 30 and SwissMedic (Swiss FDA equivalent) clearance on November 8. This study — the first to evaluate LSD’s therapeutic applications in over 35 years — will be initiated in early 2008.
